The Biden administration’s implementation of the Medicare drug pricing program could alter drugmaker strategy on biosimilars, highlighted by the recent approval of a follow-on biologic to a Johnson & Johnson drug tapped for negotiations.
The FDA’s approval last month of Amgen’s Wezlana as an interchangeable biosimilar to Johnson & Johnson’s Stelara raised the possibility that the drug to treat multiple inflammatory diseases could be pulled from the price negotiation program put in place by the 2022 Inflation Reduction Act.
Stelara is the first instance of a drug on the price negotiation list with an approved biosimilar expected to hit the ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.